KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Operating Leases: 2022-2025

Historic Operating Leases for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Sep 2025 value amounting to $50.0 million.

  • Recursion Pharmaceuticals' Operating Leases fell 44.13% to $50.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.0 million, marking a year-over-year decrease of 44.13%. This contributed to the annual value of $67.2 million for FY2024, which is 35.78% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Operating Leases stood at $50.0 million for Q3 2025, which was down 6.31% from $53.4 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Operating Leases ranged from a high of $89.5 million in Q3 2024 and a low of $44.4 million during Q4 2022.
  • Moreover, its 3-year median value for Operating Leases was $51.2 million (2023), whereas its average is $59.7 million.
  • In the last 5 years, Recursion Pharmaceuticals' Operating Leases spiked by 80.32% in 2024 and then plummeted by 44.13% in 2025.
  • Quarterly analysis of 4 years shows Recursion Pharmaceuticals' Operating Leases stood at $44.4 million in 2022, then rose by 11.50% to $49.5 million in 2023, then surged by 35.78% to $67.2 million in 2024, then tumbled by 44.13% to $50.0 million in 2025.
  • Its Operating Leases was $50.0 million in Q3 2025, compared to $53.4 million in Q2 2025 and $56.0 million in Q1 2025.